Skip Navigation



International Immunology Advance Access published online on October 23, 2009

International Immunology, doi:10.1093/intimm/dxp103
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
21/12/1341    most recent
dxp103v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sisto, M.
Right arrow Articles by D'Amore, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sisto, M.
Right arrow Articles by D'Amore, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Japanese Society for Immunology. 2009. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Induction of TNF-alpha-converting enzyme-ectodomain shedding by pathogenic autoantibodies

Margherita Sisto1,*, Sabrina Lisi1,*, Dario Domenico Lofrumento2, Maria Antonia Frassanito3, Liana Cucci1, Simona D'Amore4, Vincenzo Mitolo1 and Massimo D'Amore4

1 Section of Cell Biology, Department of Human Anatomy and Histology, University of Bari Medical School, piazza Giulio Cesare 1, I-70124 Bari, Italy
2 Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
3 Department of Internal Medicine and Clinical Oncology
4 Section of Rheumatology, Department of Internal Medicine and Public Medicine, University of Bari Medical School, piazza Giulio Cesare 1, I-70124 Bari, Italy

Correspondence to: M. Sisto; E-mail: m.sisto{at}anatomia.uniba.it

The release of the soluble form of tumor necrosis factor (TNF)-alpha from the plasma membrane occurs through the activation of the secretase tumor necrosis factor-alpha-converting enzyme (TACE). The current study was designed to examine whether the anti-Ro/SSA autoantibodies (Abs) are capable to regulate TACE expression in non-neoplastic human salivary gland epithelial cells (SGEC) cultures. We investigated the effect of anti-Ro/SSA Abs on the localization and abundance of cell-surface TACE and on TACE pro-domain-shedding and activation. In addition, the potential physiological consequences of TNF-alpha blockage by the biological agent Adalimumab on post-translational regulation of TACE are discussed. Anti-Ro/SSA Abs were purified from IgG fractions of patients with primary Sjögren's syndrome, using Sepharose 4B-Ro/SSA affinity columns. Flow cytometry, reverse transcription–PCR, western blot and immunohistochemistry were used to study TACE expression on SGEC and TACE regulation by Abs. Our study demonstrated a dose-dependent increase of TACE messenger RNA (mRNA) expression in anti-Ro/SSA Abs-treated SGEC, followed by internalization, pro-domain shedding and activation of TACE protein, suggesting that increased TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA Abs-stimulated SGEC. Adalimumab treatment brought TACE mRNA and surface TACE expression to levels than those observed in untreated SGEC. These data suggest that the effect of anti-Ro/SSA Abs on TACE expression and intracellular distribution is exerted by TNF-alpha production.

Keywords: adalimumab, autoantibodies, epithelial cells, shedding, TACE


* These authors contributed equally to this study and both are equally considered as ‘first author’.

Transmitting editor: A. Falus

Received 7 May 2009, accepted 18 September 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.